WO2006014628A8 - Procédés d’évaluation des risques de développement de maladies cardio-vasculaires - Google Patents

Procédés d’évaluation des risques de développement de maladies cardio-vasculaires

Info

Publication number
WO2006014628A8
WO2006014628A8 PCT/US2005/025551 US2005025551W WO2006014628A8 WO 2006014628 A8 WO2006014628 A8 WO 2006014628A8 US 2005025551 W US2005025551 W US 2005025551W WO 2006014628 A8 WO2006014628 A8 WO 2006014628A8
Authority
WO
WIPO (PCT)
Prior art keywords
risk
methods
cardiovascular disease
assessing
development
Prior art date
Application number
PCT/US2005/025551
Other languages
English (en)
Other versions
WO2006014628A1 (fr
Inventor
Jay W Heinecke
John F Oram
Original Assignee
Univ Washington
Jay W Heinecke
John F Oram
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Jay W Heinecke, John F Oram filed Critical Univ Washington
Priority to US11/572,308 priority Critical patent/US7749729B2/en
Priority to EP05773538A priority patent/EP1787116A4/fr
Priority to CA2581929A priority patent/CA2581929C/fr
Publication of WO2006014628A1 publication Critical patent/WO2006014628A1/fr
Publication of WO2006014628A8 publication Critical patent/WO2006014628A8/fr
Priority to US12/785,332 priority patent/US20100297680A1/en
Priority to US14/502,668 priority patent/US20170016924A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
    • Y10T436/201666—Carboxylic acid

Abstract

Cette invention se rapporte à des tests, procédés et trousses de diagnostic utiles pour évaluer chez un sujet les risques de cas pathologique relié notamment à la présence de produits de l’oxydation de lipoprotéines de haute densité (HDL). Il est utile de mesurer la quantité d’un ou de plusieurs produits de l’oxydation de HDL présents dans le sang pour évaluer les risques de développement d’une maladie, la gravité d’une maladie ou la réponse au traitement de la maladie concernée, notamment dans le cas de maladies cardio-vasculaires.
PCT/US2005/025551 2004-07-19 2005-07-19 Procédés d’évaluation des risques de développement de maladies cardio-vasculaires WO2006014628A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/572,308 US7749729B2 (en) 2004-07-19 2005-07-19 Methods for assessing the risk for development of cardiovascular disease
EP05773538A EP1787116A4 (fr) 2004-07-19 2005-07-19 Procedes d'evaluation des risques de developpement de maladies cardio-vasculaires
CA2581929A CA2581929C (fr) 2004-07-19 2005-07-19 Procedes d'evaluation des risques de developpement de maladies cardio-vasculaires
US12/785,332 US20100297680A1 (en) 2004-07-19 2010-05-21 Methods for assessing the risk for development of cardiovascular disease
US14/502,668 US20170016924A1 (en) 2004-07-19 2014-09-30 Methods for assessing the risk for development of cardiovascular disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71451704P 2004-07-19 2004-07-19
US60/714,517 2004-07-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/572,308 A-371-Of-International US7749729B2 (en) 2004-07-19 2005-07-19 Methods for assessing the risk for development of cardiovascular disease
US12/785,332 Division US20100297680A1 (en) 2004-07-19 2010-05-21 Methods for assessing the risk for development of cardiovascular disease

Publications (2)

Publication Number Publication Date
WO2006014628A1 WO2006014628A1 (fr) 2006-02-09
WO2006014628A8 true WO2006014628A8 (fr) 2006-08-17

Family

ID=35787424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025551 WO2006014628A1 (fr) 2004-07-19 2005-07-19 Procédés d’évaluation des risques de développement de maladies cardio-vasculaires

Country Status (4)

Country Link
US (3) US7749729B2 (fr)
EP (1) EP1787116A4 (fr)
CA (1) CA2581929C (fr)
WO (1) WO2006014628A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
US8628935B2 (en) * 2009-08-19 2014-01-14 The Cleveland Clinic Foundation PON1 as a marker for heart failure
CN102812359A (zh) * 2009-11-13 2012-12-05 Bg医药公司 心肌梗死的风险因子和预测
CA2829153A1 (fr) * 2011-03-10 2012-09-13 The Regents Of The University Of California Compositions et methodes de determination de risque d'accident cardiovasculaire occlusif
KR101177643B1 (ko) 2011-03-11 2012-08-27 영남대학교 산학협력단 등전점 전기영동 및 바이오칩을 이용한 노화 및 노화 관련 질환의 진단방법 및 진단키트
US20130017556A1 (en) * 2011-04-22 2013-01-17 Pritchard Jr Jr Kirkwood A Assays for hdl biomolecular interactions
US10466247B2 (en) 2012-11-20 2019-11-05 Becton, Dickinson And Company System and method for diagnosing sensor performance using analyte-independent ratiometric signals
US10379125B2 (en) 2013-12-27 2019-08-13 Becton, Dickinson And Company System and method for dynamically calibrating and measuring analyte concentration in diabetes management monitors
JP6826601B2 (ja) * 2015-12-22 2021-02-03 サイテック インダストリーズ インコーポレイテッド 複合材部材のための離型性表面材
CN111175522B (zh) * 2018-11-09 2023-04-07 上海交通大学医学院附属瑞金医院 氧化型高密度脂蛋白的应用
JP7193082B2 (ja) * 2018-12-28 2022-12-20 サンスター株式会社 血管組織機能低下リスクマーカー
EP3934650A4 (fr) * 2019-03-08 2022-11-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Procédés d'évaluation du risque de maladie cardiovasculaire ou de maladie inflammatoire à l'aide d'une sonde lipidique non échangeable
CN111743885B (zh) * 2020-08-17 2022-03-15 山东省科学院生物研究所 一种对羟基苯乙酸在预防和/或治疗心血管疾病中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3370334B2 (ja) * 1993-09-29 2003-01-27 栄次 松浦 酸化リポタンパク質の測定法およびその用途
US6268220B1 (en) * 1996-09-09 2001-07-31 Washington University Diagnostic method for atherosclerosis
AUPQ429399A0 (en) * 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use
BR0206273A (pt) * 2001-01-02 2006-11-21 Cleveland Clinic Foundation testes diagnósticos para caracterizar o risco de um paciente humano de desenvolver ou apresentar doença cardiovascular e para avaliar um agente terapêutico para doença cardiovascular em um sujeito suspeito de apresentar ou apresentando doença cardiovascular, e, kit
US7780950B2 (en) * 2002-01-02 2010-08-24 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
EP2306192B1 (fr) * 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Marqueurs de risque pour maladies cardiovasculaires
US8241861B1 (en) * 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease

Also Published As

Publication number Publication date
US7749729B2 (en) 2010-07-06
EP1787116A1 (fr) 2007-05-23
US20100297680A1 (en) 2010-11-25
CA2581929C (fr) 2016-10-18
US20080261250A1 (en) 2008-10-23
WO2006014628A1 (fr) 2006-02-09
EP1787116A4 (fr) 2008-05-28
US20170016924A1 (en) 2017-01-19
CA2581929A1 (fr) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2006014628A8 (fr) Procédés d’évaluation des risques de développement de maladies cardio-vasculaires
Lasisi et al. Salivary creatinine and urea analysis in patients with chronic kidney disease: a case control study
Jurca et al. Assessing cardiorespiratory fitness without performing exercise testing
Danesh et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis
Wainstein et al. Combining skin prick, immediate skin application and specific‐IgE testing in the diagnosis of peanut allergy in children
Jones et al. Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations
Sun et al. Childhood obesity predicts adult metabolic syndrome: the Fels Longitudinal Study
Kokura et al. High nutritional-related risk on admission predicts less improvement of functional independence measure in geriatric stroke patients: a retrospective cohort study
Fahey et al. How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales
WO2006026020A3 (fr) Fibronectine oncofoetale en tant que marqueur de maladies et d'autres conditions et procedes pour la detection de la fibronectine oncofoetale
WO2005114190A3 (fr) Procedes pour identifier des marqueurs biologiques
Järvholm et al. Characteristics of adolescents with poor mental health after bariatric surgery
Slee et al. The relationship between malnutrition risk and clinical outcomes in a cohort of frail older hospital patients
Chatindiara et al. Associations between nutrition risk status, body composition and physical performance among community‐dwelling older adults
WO2005020784A3 (fr) Signatures d'expression genique de cellules de substitution permettant d'evaluer l'etat physique d'un patient
WO2006073682A3 (fr) Test diagnostique
WO2008061149A3 (fr) Procédés et compositions de diagnostic et de pronostic de la sténose d'artère rénale
WO2008137762A3 (fr) Procédés de diagnostic et de traitement de la maladie de crohn
Basketter et al. Assessing the potency of respiratory allergens: uncertainties and challenges
Felicio et al. Inflammatory mediators, muscle and functional performance of community-dwelling elderly women
WO2006099543A3 (fr) Methodes d'evaluation de la toxicite induite par des anticorps
Bolepalli et al. Determining the association between oral malodor and periodontal disease: a case control study
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
JP2008504551A5 (fr)
CA2575405A1 (fr) Procede servant a diagnostiquer une fibrose du foie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 553289

Country of ref document: NZ

Ref document number: 2005773538

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2581929

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2005773538

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11572308

Country of ref document: US